Credit: Metronom Health
Chinese medical device innovation hub Dinova Medtech and US-based medical device company Metronom Health have established a joint venture to develop and sell a continuous glucose monitoring system in China.
WHY IT MATTERS
Traditional fingerstick glucose meters can only provide information about intermittent glucose levels and the pain that comes with finger pricking can potentially reduce patients adherence. By inserting a sensor into the subcutaneous tissue along with a transmitter that sends the data to a smart device, CGMs can provide continuous glucose information to detect glycemic variability.
According to a press release, Metronom Health has developed a minimally invasive CGM system that uses proprietary Opto-enzymatic technology – in contrast to most CGMs that use electrochemical technology – to capture both high and low ranges of a patient s glucose profile. The company claims that this will be done with high accuracy and also asserts th
Share this article
Share this article
ResearchAndMarkets.com s offering.
Diabetes is one of the seven leading causes of death and disability across the world. According to the World Health Organization (WHO), more than 1.6 million deaths are directly attributed to diabetes each year. In 2019, the global expenditure on diabetes treatment and disease management was estimated to be over USD 750 billion; this is indicative of the significant burden on patients and the global healthcare system.
Timely glucose monitoring helps prevent unwanted glucose fluctuations (hyperglycemia/hypoglycemia), which are known to have serious implications, including (but not limited to) kidney damage, cardiovascular complications, visual impairment, diabetic ketoacidosis and circulatory defects (some of which are known to progress to a stage requiring amputation). The current gold standard for self-monitoring of blood glucose level involves the use glucose meters. These are compact devices designed to